[Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003757
German
Original Title:
Ravulizumab (atypisches haemolytisch-uraemisches Syndrom)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a20-68.html
Year Published:
2020
URL for published report:
https://www.iqwig.de/download/a20-68_ravulizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Atypical Hemolytic Uremic Syndrome
- Antibodies, Monoclonal, Humanized
- Complement Inactivating Agents
Keywords
- Ravulizumab
- Atypical Hemolytic Uremic Syndrome
- Benefit Assessment
- NCT02949128
- NCT03131219
- NCT01193348
- NCT0119497
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.